Durable Improvement in Patient Reported Outcomes across DLQI Subdomains Over 48 Weeks in Chronic Plaque Psoriasis Patients Treated with Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). J of Skin [Internet]. 2019 Mar. 11 [cited 2025 Jun. 8];3(2):175. Available from: https://skin.dermsquared.com/skin/article/view/532